Since 2007, DOSIsoft wanted to improve Nuclear Medicine dosimetry using our expertise in Radiation Oncology and advancing technology. Radionuclides can be used for imaging or treatment (radioembolization). According to World Nuclear Association, 26% of the world population (coming from developed countries) have a 1.9% frequency of diagnostic nuclear medicine per year, and the frequency of therapy with radioisotopes is about one tenth of this.
Targeted Radionuclide Therapy (TRT) is rapidly evolving because of its high potential and decreased risk of side effects. TRT is becoming the treatment of choice for unresectable cancers, or other cancers in need of radiation, post or pre-surgery, such as liver cancers. As of 2012, according to the Cancer Research UK, there have been 782 thousand diagnosed new cases of liver cancer worldwide. 28% of liver cancers pertain to hepatocellular carcinoma (HCC). Yttrium-90 (Y-90) is the most efficient treatment used for HCC, and is the radionuclide used for this targeted therapy.
Advances of Nuclear Medicine
Major clinical applications are starting to use 177Lu for neuroendocrine tumors. Due to the high incidence of metastatic prostate cancers throughout the world, exciting new advances are using 177Lu-based agents for therapy.
As Nuclear Medicine advances, the software solutions for the analysis are becoming essential to have throughout the whole process. Innovative software solutions have been emerging to assist in precision and quality care for each patient.
Advanced algorithms are used to improve the precision of Nuclear Medicine, with highly accurate software solutions.
Our software provides the means for complete and effective treatment analysis and diagnosis.
Each software solution is geared to enhance treatment specific to each patient.
As Nuclear Medicine is upgrading its treatment, we are constantly growing and progressing software solutions to improve accuracy and precision.